• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

ENBREL FDA APPROVED FOR EXPANDED INDICATION

Article

The FDA approved Amgen and Wyeth Pharmaceuticals drug, Enbrel (etanercept), to inhibit the progression of structural damage in patients with active psoriatic arthritis and reduce its signs and symptoms.

Related Videos
Related Content
Optical Coherence Tomography in Preoperative Mapping of BCC: A Novel Approach to Optimizing Mohs Micrographic Surgery

Optical Coherence Tomography in Preoperative Mapping of BCC: A Novel Approach to Optimizing Mohs Micrographic Surgery

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
QUIZ RECAP: Test Your Knowledge of Rosacea Treatment Modalities and the Therapeutic Landscape

QUIZ RECAP: Test Your Knowledge of Rosacea Treatment Modalities and the Therapeutic Landscape

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Article
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Article
© 2024 MJH Life Sciences

All rights reserved.